Diabetes Knowledge into Practice Podcast (Liberum IME)

This is a special episode brought to you in association with Hepatology Knowledge into Practice.

People with type 2 diabetes or obesity are at higher risk of developing non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH). Some estimates report a prevalence of NAFLD of 60% in people with type 2 diabetes, rising to 78% in those who also have obesity. So what’s behind this link?

In this podcast episode, Professor Giulio Marchesini explores the relationships between NAFLD, type 2 diabetes and obesity and offers advice for healthcare professionals caring for people with one or more of these conditions.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures: Prof. Giulio Marchesini declares the following:

Advisory Board: Novartis, Eli Lilly, Gilead, MSD, Pfzier, Astra-Zeneca

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Join Prof. Francesco Giorgino and Dr. Shehla Shaikh as they discuss strategies to help support type 2 diabetes patients during cultural events, such as observation of Ramadan.

For more free education, go to ⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠. Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Shehla Shaikh

Dr. Shaikh declares no current financial conflict of interest

Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

The ADA 2022 was full of interesting symposia, updates on ongoing clinical trials, and a draft of an updated ADA-EASD consensus report. This year’s conference also put particular emphasis on weight management in the setting of type 2 diabetes as well as its associated cardiovascular and kidney comorbidities.

Join us as we speak to Professor Jennifer Green about her conference highlights, including:

- Draft ADA-EASD Consensus Report

- Results from the SURMOUNT-1 clinical trial of tirzepatide in people with obesity

- Further data for dual and triple incretin agonists and their potential future role

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Jennifer Green declares the following financial relationships from the past 24 months:

Consultant: AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada (ended), Pfizer, NovoNordisk, Sanofi/Lexicon(ended), ICON/Vertex, and Anji.

Research support: Boehringer Ingelheim/Lilly, Merck, and Roche.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

This is a special episode brought to you in association with Hepatology Knowledge into Practice. Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease, of which an advanced form is non-alcoholic steatohepatitis (NASH). But how does this condition develop, and why is it associated with poor outcomes? In this podcast episode, Professor Zobair Younossi discusses the latest evidence on the pathogenesis and pathophysiology of NASH, and how it can lead to poor outcomes.  

By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.   

References: 

Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1.   

Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020 Jan 1;41(1):bnz009.  

Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care. 2018 Feb;41(2):341-347.  Disclosures: Prof. Zobair Younossi declares XYZ. All conflicts of interest have been mitigated prior to this activity.  

Disclosures:

Professor Zobair Younossi declares the following:

Consultant: Merck, Gilead, Siemens, Intercept, Bristol Myers Squibb

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: 

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

GLP-1 receptor agonists including semaglutide have been shown to offer benefits for glycemic control, weight loss and cardiovascular protection in type 2 diabetes. But where a patient requires more glycemic control, would a higher dose be of help?

The SUSTAIN FORTE trial was a randomized, double-blind, phase 3B trial that aimed to establish whether a higher dose of semaglutide was superior to the highest approved maintenance dose for glycemic control. Join Dr Juan Pablo Frias for a summary of the trial data and its potential implications for clinical practice.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

Reference:

Frías JP, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574.

Disclosures:

Dr Juan Pablo Frías declares the following:

Grants/Research Support, Advisory Boards, Honoraria receipt - Novo Nordisk, Eli Lilly, Sanofi, Pfizer

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding Information

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

This year saw the regulatory approval of the first dual GIP/GLP-1 dual agonist for type 2 diabetes. With several other multi-agonists in development, what does this mean for clinicians caring for people with type 2 diabetes?

Join Prof. Filip Knop for an overview of these new and emerging agents.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Filip Knop declares the following financial relationships from the past 24 months:

Honorarium recipient: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi

Speakers Bureau: AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi

Consultant (Occasional): AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi

Advisor or Review Panel member: Eli Lilly, Novo Nordisk, Sanofi

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Naveed Sattar declares the following financial relationships from the past 24 months: 

Advisory - Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi

Consulting - Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi

Speaker honoraria - Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi

Grant funding - AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Efpeglenatide for type 2 diabetes

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

The last two years have provided updated guidelines on management of chronic kidney disease in type 2 diabetes alongside new regulatory approvals of pharmacotherapies. In this episode we speak to Dr David Cherney about the implications of these updates and advancements.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Dr David Cherney declares the following financial relationships from the past 24 months:

Honoraria: Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene and Novo-Nordisk

Grant/Research support: Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

The importance of weight loss in type 2 diabetes was a major topic at the recent American Diabetes Association (ADA) 2022 Scientific Sessions. As weight management is a complex issue affected by both genetic and environmental factors, we shed light on the latest advances in obesity care for individuals with type 2 diabetes.

Join us as we examine the effect of lifestyle interventions, metabolic surgery and the latest pharmaceutical agents, and discuss the state of the field with Dr Robert Kushner.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Dr Robert Kushner declares the following financial relationships from the past 24 months:

Consultant: Lilly, Pfizer

Board member: Novo Nordisk, WW

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonist, tirzepatide. Join Prof Carol Wysham for an examination of the clinical data from these trials and their potential impact on type 2 diabetes management.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

Learning objective

After listening to this podcast, learners will be able torecall the results of recent clinical trials for GIP/GLP-1 dual agonists

References available here

Disclosures

Prof. Carol Wysham declares the following financial relationships from the past 24 months:

Research Funding: Novo Nordisk; Eli Lilly

Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

Join Prof. Francisco Giorgino & Dr. Richard E. Pratley as they discuss their highlights from the 83rd American Diabetes Association (ADA 2023) congress. The congress featured over 200 scientific sessions and symposia, and 1,400 posters. Among the topics discussed are trials investigating therapies to treat obesity in patients with type 2 diabetes (T2D), as well as discussion about remission and what it really means for T2D.

For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠) or connect on ⁠LinkedIn⁠. Disclosures

Prof. Francisco Giorgino:

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Richard E. Pratley

Research grant: Dompe, Novo Nordisk

Honoraria for lectures, presentations and education events: Merck, Novo Nordisk

Consulting: Bayer AG, Endogenex Inc., Gasherbrum Bio Inc., Henguri (USA) Ltd. Intas Pharmaceuticals Inc. Eli Lilly, Merck, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., Sun Pharmaceutical Industries

Target Audience:

Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists

Geographic: Global (ex US and UK audiences)

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Heterogeneity across available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes means that agents should be prescribed based on patient characteristics and preferences. So how can we best make that decision?

Join Dr Harpreet Bajaj for a discussion of tailoring GLP-1 RA regimens to patient characteristics, including considerations for dosing and treatment intensification.

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment.

References available here

Dr Harpreet Bajaj declares the following financial relationships from the past 24 months:

Grants/Research Support: Eli Lilly, Novo Nordisk, Sanofi

Liberum IME staff, ACHL staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

This year’s EASD was a hybrid event, with delegates able to join either in person in Stockholm, or online via the virtual platform. As usual, the congress featured a huge number of presented abstracts, symposia and other sessions. This year also saw the publication of the updated ADA-EASD consensus report on the management of hyperglycaemia in type 2 diabetes.

Join us as we speak to Professor Apostolos Tsapas about his conference highlights, including:

- 2022 ADA-EASD consensus report on the management of hyperglycaemia in type 2 diabetes

- 44-year follow-up results from the UKPDS trial

- Results from the DELIVER trial of dapagliflozin in heart failure

- New data on once-weekly insulins 

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com.

Learning objectives and references available here

Disclosures:

Prof. Apostolos Tsapas declares the following financial relationships from the past 24 months:  

Consultant: Novo Nordisk

Educational grant support: Eli Lilly 

Investigator: Boehringer Ingelheim

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S  has had no influence on the content of this education.

The 2022 Standards of Medical Care in Diabetes is published every year by the American Diabetes Association to reflect the latest available clinical evidence. The most significant updates this year include a lower age to begin screening for prediabetes and diabetes, an increased emphasis on individualization of treatment, and further recommendations around the use of technologies such as continuous glucose monitoring and treatment of obesity.

To hear more about some of these updates and their rationale, we’re joined by Professor Anne Peters, a member of the ADA’s Professional Practice Committee which reviews and updates the Standards.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Anne Peters disclosures are as follows:

Participation on an advisory board - Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, ShouTi Inc, Vertex, Zealand

Research support - Abbott Diabetes Care, Dexcom, Insulet

Stock - Teladoc

Stock options - Omada Health

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well.

For more free education, go to diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice⁠) or connect on LinkedIn⁠.

Disclosures

Prof. Francisco Giorgino:

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Vanita Aroda:

Consulting: Applied Therapeutics, Fractyl, Pfizer, Novo Nordisk, Sanofi

Research Support: Applied Therapeutics, Eli Lilly, Fractyl, Novo Nordisk, Sanofi

Target Audience:

Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists

Geographic: Global (ex US and UK audiences)

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

An introduction to the podcast - who we are, and why we're doing this

In late 2020, we published an episode looking at the management of diabetes and heart failure when both present together. Since then, a wealth of evidence has been published on the effects of sodium glucose cotransporter type 2 (SGLT2) inhibitors in people with heart failure with or without type 2 diabetes. These findings have led to expanded indications for some of these agents to include heart failure. Today we will examine these data and their relevance in clinical practice in the setting of type 2 diabetes with heart failure. 

Joining us to discuss what these data mean for clinical practice is Prof. Javed Butler, who is Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Centre in Jackson, Mississippi. 

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. 

References available here

Disclosures:  

Prof. Javed Butler declares the following:

Consultant: Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharma,  Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical, and Vifor 

Speakers Bureaus: Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Janssen 

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. 

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. 

Funding: 

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

Join Prof. Francesco Giorgino and Dr. Erika Bezerra Parente as they identify some takeaways from EASD 2023, including data and discussions on treatment non-adherence, SGLT2 inhibitors, and stigma

For more free education, go to ⁠diabetes.knowledgeintopractice.com⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠@dkipractice⁠⁠) or connect on ⁠LinkedIn⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Erika Bezerra Parente

Honoraria for lectures, presentations and education events: Sanofi

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Darren McGuire as they discuss personalisation of treatment for patients with both type 2 diabetes and cardiovascular disease.

For more free education, go to ⁠⁠⁠⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠⁠⁠⁠@dkipractice⁠⁠⁠⁠⁠⁠) or connect on ⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Darren K. McGuire

Clinical trial leadership:

- Former: Esperion, AstraZeneca, CSL Behring

- Current: Novo Nordisk, Lilly USA, Pfizer, Boehringer Ingelheim, NewAmsterdam

Consultancy:

- Former: Merck & Co

- Current: Lilly USA, Boehringer Ingelheim, Novo Nordisk, Bayer, Lexicon, Altimmune, Esperion, Intercept Pharmaceuticals, Applied Therapeutics

Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education. Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Join Prof. Francesco Giorgino and Dr. Alice Cheng for a discussion on the importance of being culturally sensitive during shared decision-making in type 2 diabetes care.

For more free education, go to ⁠⁠diabetes.knowledgeintopractice.com⁠⁠⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (⁠⁠@dkipractice⁠⁠⁠) or connect on ⁠⁠LinkedIn⁠⁠⁠.

Faculty disclosures

Prof. Francesco Giorgino

Grants or contracts: Eli Lilly, Roche Diabetes Care

Consulting: Eli Lilly, Novo Nordisk

Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim

Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune

Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE

Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk

Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi

Dr. Alice Cheng

Advisory Board: Abbott, AstraZeneca, Bayer

Speakers Bureau: Abbott, Amgen, AstraZeneca, Bausch, Bayer

Funding Information:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

Accreditation information

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

This is a special episode brought to you in association with Hepatology Knowledge into Practice.

NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future.

Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

References are available here

Disclosures:

Prof. Philip Newsome declares the following:

Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals

Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Description:

A year ago, we published an episode looking at diabetes management in the context of ongoing restrictions in many parts of the world. Since then, a wealth of clinical data has continued to be published on the bidirectional relationship between diabetes and Covid-19, so today we’re taking a closer look at these data.

We’re joined by Professor Partha Kar, National Specialty Advisor, Diabetes for NHS England, to discuss what the data mean for clinical practice.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

• Kamrath C, et al. Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19 Pandemic in Germany: Results From the DPV Registry. Diabetes Care. 2022 Jan 17:dc210969.
• Gottesman BL, et al. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. JAMA Pediatr. 2022 Apr 1;176(4):414-415.
• McGlacken-Byrne SM, et al. The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A multi-centre study of the first COVID-19 wave. Diabet Med. Sep 2021;38(9):e14640.
• Barrett CE, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. Jan 14 2022;71(2):59-65.
• Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 Mar 21:S2213-8587(22)00044-4.
• Rathmann W, et al. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022 Mar 16:1-6.
• Misra S, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 2021 Oct;9(10):671-680.
• Khunti K, et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care. 2021 Dec;44(12):2645-2655.
• Apicella M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792.
• Khunti K, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021 May;9(5):293-303.

Disclosures:

Prof. Partha Kar has no relevant disclosures to report at this time.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.

This is a special episode brought to you in association with Hepatology Knowledge into Practice.

NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developing NAFLD, how can we identify those with NASH?

In this podcast episode, we are joined by Dr Kenneth Cusi to discuss how patients can be risk stratified using non-invasive biomarkers and imaging techniques.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References:

Nones RB et al. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist? Arch Endocrinol Metab. 2017 May-Jun;61(3):276-281.

Shah AG et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12.

Newsome PN et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts 2016;9(2):65-90.

Disclosures:

Dr Kenneth Cusi disclosures are as follows:

Research Support - Poxel, Zydus, Echosens, Inventiva, Novo Nordisk

Consultant - Allergan, Altimmune, Arrowhead, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Intercept, Janssen, Pfizer, Prosciento, Madrigal, and Novo Nordisk.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.